VTV THERAPEUTICS INC- CL A (VTVT) Stock Fundamental Analysis
USA - NASDAQ:VTVT - US9183852048 - Common Stock
20.51 USD
-0.56 (-2.66%)
Taking everything into account, VTVT scores 3 out of 10 in our fundamental rating. VTVT was compared to 534 industry peers in the Biotechnology industry. VTVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VTVT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VTVT has reported negative net income.
In the past year VTVT has reported a negative cash flow from operations.
VTVT had negative earnings in each of the past 5 years.
In the past 5 years VTVT always reported negative operating cash flow.
1.2 Ratios
VTVT has a Return On Assets of -73.94%. This is in the lower half of the industry: VTVT underperforms 64.04% of its industry peers.
Looking at the Return On Equity, with a value of -708.00%, VTVT is doing worse than 79.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.94% | ||
| ROE | -708% | ||
| ROIC | N/A |
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VTVT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTVT has more shares outstanding than it did 1 year ago.
VTVT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VTVT has an Altman-Z score of -16.94. This is a bad value and indicates that VTVT is not financially healthy and even has some risk of bankruptcy.
VTVT has a Altman-Z score of -16.94. This is amonst the worse of the industry: VTVT underperforms 82.40% of its industry peers.
VTVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.94 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
A Current Ratio of 4.98 indicates that VTVT has no problem at all paying its short term obligations.
With a Current ratio value of 4.98, VTVT perfoms like the industry average, outperforming 55.06% of the companies in the same industry.
A Quick Ratio of 4.98 indicates that VTVT has no problem at all paying its short term obligations.
VTVT has a Quick ratio of 4.98. This is comparable to the rest of the industry: VTVT outperforms 56.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.98 | ||
| Quick Ratio | 4.98 |
3. Growth
3.1 Past
VTVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.93%, which is quite good.
VTVT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.30%.
The Revenue for VTVT have been decreasing by -18.10% on average. This is quite bad
EPS 1Y (TTM)13.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.48%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 4.92% on average over the next years.
The Revenue is expected to grow by 112.47% on average over the next years. This is a very strong growth
EPS Next Y0.14%
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
EPS Next 5Y4.92%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VTVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTVT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VTVT's earnings are expected to decrease with -4.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
5. Dividend
5.1 Amount
No dividends for VTVT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VTVT (11/3/2025, 11:58:29 AM)
20.51
-0.56 (-2.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners39.63%
Inst Owner Change-0.11%
Ins Owners0.63%
Ins Owner Change0%
Market Cap65.43M
Revenue(TTM)17.00K
Net Income(TTM)-19555000
Analysts82.5
Price Target36.21 (76.55%)
Short Float %1.35%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.98%
Min EPS beat(2)-9.33%
Max EPS beat(2)7.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3848.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 23.69 | ||
| P/tB | 23.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.12
EYN/A
EPS(NY)-3.82
Fwd EYN/A
FCF(TTM)-6.9
FCFYN/A
OCF(TTM)-6.9
OCFYN/A
SpS0.01
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -73.94% | ||
| ROE | -708% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.98 | ||
| Quick Ratio | 4.98 | ||
| Altman-Z | -16.94 |
F-Score1
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)7.41%
Cap/Depr(5y)4.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.48%
EPS Next Y0.14%
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
EPS Next 5Y4.92%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%
EBIT growth 1Y-12.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.52%
OCF growth 3YN/A
OCF growth 5YN/A
VTV THERAPEUTICS INC- CL A / VTVT FAQ
What is the fundamental rating for VTVT stock?
ChartMill assigns a fundamental rating of 3 / 10 to VTVT.
What is the valuation status of VTV THERAPEUTICS INC- CL A (VTVT) stock?
ChartMill assigns a valuation rating of 0 / 10 to VTV THERAPEUTICS INC- CL A (VTVT). This can be considered as Overvalued.
Can you provide the profitability details for VTV THERAPEUTICS INC- CL A?
VTV THERAPEUTICS INC- CL A (VTVT) has a profitability rating of 0 / 10.
Can you provide the financial health for VTVT stock?
The financial health rating of VTV THERAPEUTICS INC- CL A (VTVT) is 6 / 10.
Can you provide the expected EPS growth for VTVT stock?
The Earnings per Share (EPS) of VTV THERAPEUTICS INC- CL A (VTVT) is expected to grow by 0.14% in the next year.